Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

bapotulimab

A mouse/human cross-reactive immunoglobulin G2 (IgG2) monoclonal antibody against the immune checkpoint immunoglobulin-like domain containing receptor 2 (ILDR2; Chromosome 1 Open Reading Frame 32; C1orf32), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, bapotulimab targets, binds to and inhibits ILDR2, thereby blocking the immunosuppressive activity of ILDR2. This prevents ILDR2-mediated inhibition of T-cell activities and induces a cytotoxic T-lymphocyte (CTL) response against tumor cells. ILDR2, a type I transmembrane protein belonging to the B7 family of immunomodulatory receptors, negatively regulates T-cell responses.
Synonym:anti-ILDR2 inhibitor BAY1905254
anti-ILDR2 monoclonal antibody BAY 1905254
anti-immunoglobulin-like domain containing receptor 2 MoAb BAY1905254
ILDR2 function-blocking antibody BAY1905254
immune checkpoint inhibitor BAY1905254
Code name:BAY 1905254
BAY-1905254
BAY1905254
Search NCI's Drug Dictionary